<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03191513</url>
  </required_header>
  <id_info>
    <org_study_id>HR-16/17-4397</org_study_id>
    <nct_id>NCT03191513</nct_id>
  </id_info>
  <brief_title>The Acute Effects of Interesterification of Commercially Used Fats on Postprandial Fat Metabolism</brief_title>
  <acronym>INTERMET</acronym>
  <official_title>The Acute Effects of Interesterification of Commercially Used Fats on Postprandial Fat Metabolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>King's College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate whether there are differences in postprandial&#xD;
      metabolic indices following interesterified fats used commercially versus the corresponding&#xD;
      un-interesterified blend.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aim: The current study aims to investigate the acute effects of commercially relevant&#xD;
      interesterified 'hardstock' versus the corresponding un-interesterified blend on 8 h&#xD;
      postprandial fat metabolism.&#xD;
&#xD;
      Hypothesis: Interesterification of a palm kernel and palm stearin fat blend, to produce a fat&#xD;
      with a higher proportion of palmitic acid in the middle position of the triglyceride (TAG;&#xD;
      but the same fatty acid composition), will alter postprandial lipid metabolism.&#xD;
&#xD;
      Subjects: Participants will include 24 healthy male and female (postmenopausal) volunteers&#xD;
      aged between the ages of 45 and 75 years (since during this age metabolic changes start to&#xD;
      take place).&#xD;
&#xD;
      Power calculation: Based on previous studies carried out by our group at King's College&#xD;
      London, a sample size of 10 males and 10 females is required to detect a (clinically&#xD;
      relevant) difference (for males and females separately) between means of 0.3 mmol/L maximal&#xD;
      difference in 8 h plasma TAG concentration (standard deviation 0.33 mmol/L, significance&#xD;
      level (alpha) of 0.05 and 80% power). 12 males and 12 females will be recruited to allow for&#xD;
      a 20% drop out rate.&#xD;
&#xD;
      Expected value:The study will provide novel information on the acute effects of commercially&#xD;
      relevant processed fats on postprandial lipaemia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 12, 2017</start_date>
  <completion_date type="Actual">May 27, 2018</completion_date>
  <primary_completion_date type="Actual">May 15, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under plasma TAG concentration/ time curve</measure>
    <time_frame>Up to 8 hours</time_frame>
    <description>Postprandial area under plasma TAG concentration/ time curve</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postprandial lipaemic response</measure>
    <time_frame>Up to 8 hours</time_frame>
    <description>Postprandial plamsa total fatty acid composition and non esterifed fatty acid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positional composition retention (chylomicron)</measure>
    <time_frame>Up to 6 hours</time_frame>
    <description>Postprandial chylomicron TAG concentration and composition, TAG sn-2 fatty acid composition, total protein, apoB100 and apoB48</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Isotope lablelled parameters</measure>
    <time_frame>Up to 8 hours</time_frame>
    <description>In sub-group, n=12, postprandial 13C TAG concentration and breath CO2 13C</description>
  </other_outcome>
  <other_outcome>
    <measure>Lipoprotein particle size and number</measure>
    <time_frame>Up to 8 hours</time_frame>
    <description>Lipoprotein size (LDL, VLDL and HDL) and composition (total and small LDL, large VLDL and total and large HDL) measured by NMR</description>
  </other_outcome>
  <other_outcome>
    <measure>2 and 3 MCPD and glycidyl esters</measure>
    <time_frame>Up to 8 hours</time_frame>
    <description>Postprandial plasma 2 and 3-monochloropropane-1,2-diol or 3-chloropropane-1,2-diol glycidyl esters</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy Adults</condition>
  <condition>Postmenopausal Women</condition>
  <arm_group>
    <arm_group_label>Interesterified</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Interesterified blend of palm kernal and plam stearin. 50g fat.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Un-interesterified</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Un-interesterified blend of palm kernal and plam stearin. 50g fat.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rapeseed oil. 50g fat.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Interesterified blend of palm kernal and plam stearin</intervention_name>
    <description>50 g fat provided as interesterified palm kernal and palm sterin blend in a single meal (sub-group, n=12, also have 75 mg 13C labelled tripalmatin and 1.2 g / kg body water deuterated water)</description>
    <arm_group_label>Interesterified</arm_group_label>
    <other_name>Interesterified blend</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Un-interesterified blend of palm kernal and plam stearin</intervention_name>
    <description>50 g fat provided as un-interesterified palm kernal and palm sterin blend in a single meal (sub-group, n=12, also have 75 mg 13C labelled tripalmatin and 1.2 g / kg body water deuterated water)</description>
    <arm_group_label>Un-interesterified</arm_group_label>
    <other_name>Un-interesterified blend</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Rapeseed oil</intervention_name>
    <description>50 g fat provided as rapeseed oil in a single meal (sub-group, n=12, also have 75 mg 13C labelled tripalmatin and 1.2 g / kg body water deuterated water)</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>Control fat</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females aged 45-75 years&#xD;
&#xD;
          -  Healthy (free of diagnosed diseases listed in exclusion criteria)&#xD;
&#xD;
          -  Able to understand the information sheet and willing to comply with study protocol&#xD;
&#xD;
          -  Able to give informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Medical history of myocardial infarction, angina, thrombosis, stroke, cancer, liver or&#xD;
             bowel disease or diabetes&#xD;
&#xD;
          -  Body mass index &lt; 20 kg/m2 or &gt; 35 kg/m2&#xD;
&#xD;
          -  Plasma cholesterol ≥7.5 mmol/L&#xD;
&#xD;
          -  Plasma triacylglycerol &gt; 3 mmol/L&#xD;
&#xD;
          -  Plasma glucose &gt; 7 mmol/L&#xD;
&#xD;
          -  Blood pressure ≥140/90 mmHg&#xD;
&#xD;
          -  Current use of antihypertensive or lipid lowering medications&#xD;
&#xD;
          -  Premenopausal (for women)&#xD;
&#xD;
          -  Alcohol intake exceeding a moderate intake (&gt; 28 units per week)&#xD;
&#xD;
          -  Current cigarette smoker (or quit withint the last 6 months)&#xD;
&#xD;
          -  ≥ 20% 10-year risk of CVD as calculated using a risk calculator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarah EE Berry, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>King's College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>King's College London</name>
      <address>
        <city>London</city>
        <zip>SE1 9NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>May 23, 2017</study_first_submitted>
  <study_first_submitted_qc>June 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2017</study_first_posted>
  <last_update_submitted>October 22, 2020</last_update_submitted>
  <last_update_submitted_qc>October 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Interesterified</keyword>
  <keyword>Postprandial</keyword>
  <keyword>Lipid</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

